STEPHANIE SILVERMAN: Open Payments
NPI 1679941363 · LONGVIEW, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,475 in 88 payments from 21 companies in 2025. Trend: 2023 $1,691 · 2024 $1,636 · 2025 $1,475
Food & beverage: $1,475
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 8 | $220 |
| AstraZeneca Pharmaceuticals LP | 13 | $200 |
| GlaxoSmithKline, LLC. | 18 | $163 |
| Novartis Pharmaceuticals Corporation | 10 | $160 |
| ABBVIE INC. | 7 | $118 |
| Novo Nordisk Inc | 6 | $104 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $87 |
| Corcept Therapeutics | 2 | $67 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $66 |
| PFIZER INC. | 3 | $46 |
Products named: LEQVIO, TRELEGY ELLIPTA, AIRSUPRA, KISUNLA, Rybelsus, UBRELVY, Kerendia, MOUNJARO.
Industry payments across TX — which companies pay providers there.
